Daiichi Sankyo, AstraZeneca Datroway wins EU approval for first-line metastatic TNBC in non-immunotherapy patientsPUBT·7 hours agoAZN-1.03%DSNKY-9.49%
Daiichi Sankyo Q1 FY26 operating profit falls 12% to JPY 85.1 billion; revenue rises 21.1% to JPY 574.7 billionPUBT·5 hours agoDSNKY-9.49%4568
Daiichi Sankyo Company: Oncology-driven revenue growth and FX gains lifted results, but profit fell on higher costsQuartr·9 hours agoDSNKY-9.49%4568
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy | AZN Stock NewsStockTitan·15 hours agoAZN-1.03%DSNKY-9.49%
Toyota Stock, SoftBank And Daiichi Sankyo Offer Reliable Japan Dividend IncomeSimplywall·Jul 27 at 10:13 AMTM-1.49%DSNKY-9.49%
Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Short Interest Up 1,183.6% in JulyMarket Beat·Jul 24 at 06:00 PMDSNKY-9.49%4568
Daiichi Sankyo’s Enhertu plus pertuzumab wins EU CHMP backing for first-line HER2+ metastatic breast cancerPUBT·Jul 24 at 06:01 AMDSNKY-9.49%4568
3 Japanese Dividend Stocks Paying Over 3% That Income Investors May Want To WatchSimplywall·Jul 22 at 04:14 PM72039984
Canon Stock And 2 Japanese Dividend Stocks Offering Steady IncomeSimplywall·Jul 18 at 12:02 AM4568SFTBY+7.58%
Toyota Stock And 2 Japanese Dividend Shares Offering Steady YieldSimplywall·Jul 12 at 04:07 PM77517203
Key facts: Wainua fails CV trial; Enhertu nears UK price dealTradingView·Jul 9 at 02:14 AMAZNAZN-1.03%
AstraZeneca Nears Enhertu Deal After 300 Million UK InvestmentGuruFocus·Jul 8 at 01:46 PMAZN-1.03%AZN
AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europebenzinga_article·Jun 29 at 11:59 AMAZNAZN-1.03%
